Compare PNC & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNC | GSK |
|---|---|---|
| Founded | 1852 | 1715 |
| Country | United States | United Kingdom |
| Employees | 55333 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.1B | 96.1B |
| IPO Year | 2010 | N/A |
| Metric | PNC | GSK |
|---|---|---|
| Price | $200.87 | $53.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 2 |
| Target Price | ★ $232.00 | N/A |
| AVG Volume (30 Days) | 2.2M | ★ 4.9M |
| Earning Date | 04-13-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.35% | 3.23% |
| EPS Growth | ★ 20.74 | N/A |
| EPS | ★ 16.59 | N/A |
| Revenue | ★ $23,099,000,000.00 | N/A |
| Revenue This Year | $16.52 | $6.81 |
| Revenue Next Year | $4.62 | $4.74 |
| P/E Ratio | ★ $12.20 | $32.75 |
| Revenue Growth | ★ 7.16 | N/A |
| 52 Week Low | $148.28 | $32.38 |
| 52 Week High | $243.94 | $61.70 |
| Indicator | PNC | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 30.55 | 37.71 |
| Support Level | $198.68 | $47.89 |
| Resistance Level | $210.75 | $60.37 |
| Average True Range (ATR) | 5.29 | 0.93 |
| MACD | -1.94 | -0.78 |
| Stochastic Oscillator | 5.19 | 1.31 |
PNC Financial is one of the three super-regional banks in the US, with around $574 billion in total assets at the end of Dec. 30, 2025. Headquartered in Pittsburgh, Pennsylvania, PNC Financial has a coast-to-coast branch network, with a strong presence in the US Midwest and Northeast. It closed its acquisition of FirstBank in January 2026, which added around $26 billion in assets to its balance sheet, and PNC is currently expanding in the Southern and Western regions of the US. The bank provides a diversified set of financial services in retail banking, commercial banking, card and treasury management, asset management, and investment banking. PNC derived around 38% of revenue from fee income and 62% from net interest income in 2025.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.